🌸 HPV Clearance vs Persistence Immune Simulator

HPV Entry Into Basal Epithelium

Placeholder: virus enters through microabrasions and infects basal cells.

• 2-8 wks: Incubation window (Placeholder timing note)
• Basal layer: Entry site (Placeholder location note)
• ~80%: Global prevalence (Placeholder lifetime exposure)
• 200+: HPV genotypes (Placeholder genotype count)

Viral entry mechanism

Placeholder: HPV virions access basal keratinocytes via epithelial microtrauma.

Placeholder callout: infection is usually asymptomatic and undetected.

Cytotoxic T-cell Immune Activation

Placeholder: adaptive immunity mobilizes T-cells against infected cells.

• ~1-3 mo: Response onset (Placeholder activation delay)
• CD8+ T-cell: Key cell type (Placeholder effector cell)
• IFN-γ: Cytokine signal (Placeholder signaling molecule)
• Pap smear: Detection method (Placeholder screening tool)

Immune surveillance activation

Placeholder: local immune cells detect and target infected keratinocytes.

Placeholder callout: cell-mediated immunity is the main clearance driver.

Resolution Within One To Two Years

Placeholder: the majority of HPV infections clear without intervention.

• ~90%: Clearance rate (Placeholder within 2 years)
• 8-14 mo: Median time (Placeholder clearance duration)
• Low: Recurrence risk (Placeholder reinfection note)
• Routine: Follow-up (Placeholder screening interval)

Natural resolution pathway

Placeholder: cleared infections leave normal epithelial architecture intact.

Placeholder callout: most patients need no further treatment.

High-Risk HPV Genomic Integration

Placeholder: high-risk types evade clearance and integrate into the genome.

• ~10%: Persistence rate (Placeholder high-risk cases)
• HPV16/18: Key genotypes (Placeholder oncogenic types)
• E6/E7: Oncoproteins (Placeholder viral proteins)
• Host genome: Integration site (Placeholder mechanism note)

Immune evasion and integration

Placeholder: persistent high-risk HPV disrupts tumor suppressor pathways.

Placeholder callout: persistence beyond 2 years raises dysplasia risk.

Progressive Cervical Dysplasia Development

Placeholder: abnormal cell layers accumulate toward precancerous change.

• CIN 1-3: CIN grading (Placeholder severity scale)
• 5-10 yrs: Progression time (Placeholder to cancer)
• Recommended: Colposcopy (Placeholder referral note)
• CIN1 often: Reversibility (Placeholder regression note)

Dysplastic progression staging

Placeholder: disordered epithelial layers replace normal stratification over time.

Placeholder callout: early detection allows treatment before invasion.